Dasatinib-Teva

Země: Nový Zéland

Jazyk: angličtina

Zdroj: Medsafe (Medicines Safety Authority)

Aktivní složka:

Dasatinib monohydrate 103.693mg equivalent to dasatinib 100 mg

Dostupné s:

Teva Pharma (New Zealand) Limited

Dávkování:

100 mg

Léková forma:

Film coated tablet

Složení:

Active: Dasatinib monohydrate 103.693mg equivalent to dasatinib 100 mg Excipient: Croscarmellose sodium Hyprolose Lactose monohydrate Magnesium stearate Microcrystalline cellulose Opadry white YS-1-7027

Druh předpisu:

Prescription

Terapeutické indikace:

Dasatinib-Teva is indicated for the treatment of adults aged 18 years or over with: · newly diagnosed chronic myeloid leukaemia (CML). · chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy. Dasatinib-Teva is indicated for the treatment of paediatric patients with: · Ph+ CML in the chronic phase. · Newly diagnosed Ph+ALL in combination with chemotherapy

Přehled produktů:

Package - Contents - Shelf Life: Blister pack, OPA/Al/PVC foil - 30 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with PP CRC and silica gel desiccant - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Datum autorizace:

2020-04-03